Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.

What Was Tested

The paper reports a study of Buserelin, published as a randomized controlled trial.

Serum concentrations of placental protein 14 (PP14), steroids and gonadotrophins were related to the outcome of IVF/intracytoplasmic sperm injection in 195 normogonadotrophic women subjected to the long protocol gonadotrophin-releasing hormone agonist (GnRHa; buserelin) pituitary down-regulation protocol and gonadotrophin stimulation (HMG or rFSH).

Patient's blood was sampled for PP14 and hormone analysis on cycle days 21, S1, S8 and on the day of oocyte retrieval.

Who Took Part

According to the abstract, 195 women were involved.

By PubMed's age tags, the people studied were adults, women only.

Pituitary down-regulation was initiated on cycle day 21 and the patients were randomized to either intranasal or s.c. administration of buserelin.

How the Study Was Run

In design terms this was a randomized study.

The women were allocated by chance, so the Buserelin group and the comparison group should start out alike.

What Was Measured

Serum concentrations of placental protein 14 (PP14), steroids and gonadotrophins were related to the outcome of IVF/intracytoplasmic sperm injection in 195 normogonadotrophic women subjected to the long protocol gonadotrophin-releasing hormone agonist (GnRHa; buserelin) pituitary down-regulation protocol and gonadotrophin stimulation (HMG or rFSH).

PubMed files the paper under topics including Buserelin, Estradiol, Fertility Agents, Female, Fertilization, Fertilization in Vitro, Follicle Stimulating Hormone and Glycodelin.

What This Means in Plain Language

The paper is a randomized study of Buserelin in 195 women.

The publication is from 2004 (Reproductive biomedicine online), a journal based in Netherlands.

More context: all human trials.